Please login to the form below

Not currently logged in
Email:
Password:

American Heart Association meeting

This page shows the latest American Heart Association meeting news and features for those working in and with pharma, biotech and healthcare.

AZ says target of $45bn sales by 2023 still achievable

AZ says target of $45bn sales by 2023 still achievable

The product has new cardiovascular outcomes data from the DECLARE-TIMI 58 trial – a must-have for diabetes therapies now – which is due for presentation at the American Heart Association (AHA) ... It will be followed by additional studies in patients

Latest news

  • Amgen's Repatha unclogs blocked arteries, says study Amgen's Repatha unclogs blocked arteries, says study

    At the American Heart Association (AHA) annual meeting this week, lead study author Stephen Nichols of the University of Adelaide in Australia reported that adding a monthly Repatha shot to daily ... The results have also been published in the Journal of

  • Sanofi plans 18 new product launches by 2020 Sanofi plans 18 new product launches by 2020

    These include cholesterol-lowering antibody alirocumab (now given the proposed trade name of Praluent) - fresh from encouraging new data presented at the American Heart Association meeting - as well a vaccine against ... the company will be keen to

  • PCSK9 inhibitor alirocumab works in statin-intolerance PCSK9 inhibitor alirocumab works in statin-intolerance

    Sanofi and Regeneron’s drug impresses at American Heart Association meeting. Sanofi and Regeneron's investigational drug alirocumab is more effective at reducing cholesterol levels than Merck &Co's Zetia in ... The ODYSSEY ALTERNATIVE trial - reported

  • Merck's ezetimibe has 'modest' benefit when added to statins Merck's ezetimibe has 'modest' benefit when added to statins

    Results presented at the American Heart Association (AHA) meeting showed that 32.7% of Vytorin-treated patients suffered a major cardiovascular event over a median seven-year follow-up period, compared

  • US FDA deems Novartis' heart failure candidate a 'breakthrough' US FDA deems Novartis' heart failure candidate a 'breakthrough'

    It also seems to boost kidney function and cardiac output. The RELAX-AHF data was first unveiled at the American Heart Association (AHA) annual meeting in Los Angeles last November and ... At the moment these patients have few treatment options beyond

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics